- Home
- AGL vs ARDX Comparison
AGL vs ARDX Comparison
Compare AGL & ARDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AGL
- ARDX
- Stock Information
- Founded
- AGL 2016
- ARDX 2007
- Country
- AGL United States
- ARDX United States
- Employees
- AGL 1076
- ARDX N/A
- Industry
- AGL Managed Health Care
- ARDX Biotechnology: Pharmaceutical Preparations
- Sector
- AGL Health Care
- ARDX Health Care
- Exchange
- AGL Nasdaq
- ARDX Nasdaq
- Market Cap
- AGL 923.1M
- ARDX 971.4M
- IPO Year
- AGL 2021
- ARDX 2014
- Fundamental
- Price
- AGL $2.15
- ARDX $3.73
- Analyst Decision
- AGL Hold
- ARDX Strong Buy
- Analyst Count
- AGL 20
- ARDX 8
- Target Price
- AGL $4.47
- ARDX $10.19
- AVG Volume (30 Days)
- AGL 5.0M
- ARDX 4.9M
- Earning Date
- AGL 05-06-2025
- ARDX 07-31-2025
- Dividend Yield
- AGL N/A
- ARDX N/A
- EPS Growth
- AGL N/A
- ARDX N/A
- EPS
- AGL N/A
- ARDX N/A
- Revenue
- AGL $5,988,958,000.00
- ARDX $361,706,000.00
- Revenue This Year
- AGL N/A
- ARDX $12.67
- Revenue Next Year
- AGL $10.11
- ARDX $32.07
- P/E Ratio
- AGL N/A
- ARDX N/A
- Revenue Growth
- AGL 23.07
- ARDX 127.33
- 52 Week Low
- AGL $1.50
- ARDX $3.21
- 52 Week High
- AGL $7.73
- ARDX $8.06
- Technical
- Relative Strength Index (RSI)
- AGL 32.82
- ARDX 43.57
- Support Level
- AGL $2.09
- ARDX $3.62
- Resistance Level
- AGL $2.37
- ARDX $3.97
- Average True Range (ATR)
- AGL 0.15
- ARDX 0.21
- MACD
- AGL 0.04
- ARDX 0.02
- Stochastic Oscillator
- AGL 14.58
- ARDX 24.29
About AGL agilon health inc.
Agilon Health Inc is transforming healthcare by empowering primary care physicians for the health of the patients. The company enables physicians to create their own Medicare-centric globally capitated line of business. The company derives its revenue from Medical services.
About ARDX Ardelyx Inc.
Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. It product Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.